시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 전두측두엽 치매 시장 - 산업 규모, 점유율, 동향, 기회, 예측 : 약제 클래스별, 적응 질환별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Frontotemporal Dementia Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Disease Indication, By Distribution Channel, By Region & Competition, 2020-2030F
상품코드 : 1778939
리서치사 : TechSci Research
발행일 : 2025년 07월
페이지 정보 : 영문 185 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,500 ￦ 6,501,000
Unprintable PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.
US $ 5,500 ￦ 7,946,000
PDF and Excel (Multi-User License) help
PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.
US $ 8,000 ￦ 11,558,000
PDF and Excel (Custom Research License) help
PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

전두측두엽 치매 시장은 2024년 2억 4,136만 달러 규모로 평가되었으며, 2030년까지 연평균 성장률 6.39%로 견고한 성장을 보일 것으로 예상됩니다.

전두측두엽 질환은 뇌의 전두엽 또는 측두엽 신경 세포의 퇴화를 특징으로 하는 신경 질환입니다. 치매, 진행성 핵상 마비, 원발성 진행성 실어증을 포함하는 이 질환은 행동, 언어, 운동 및 성격에 심각한 영향을 미쳐 일상생활 수행 능력을 저하시킵니다. 전두측두엽 변성으로도 알려진 전두측두엽 질환은 주로 전두엽과 측두엽에 영향을 미치는 뇌 질환의 한 유형입니다. 이 질환은 신경 세포의 점진적인 손실과 치매 발생을 특징으로 합니다.

시장 개요
예측 기간 2026-2030년
시장 규모 : 2024년 2억 4,136만 달러
시장 규모 : 2030년 3억 4,718만 달러
CAGR : 2025-2030년 6.39%
급성장 부문 인지기능 향상약
최대 시장 북미

예를 들어, 핀란드에서 2025년에 실시한 한 연구에서는 245명의 전두측두형 치매(FTD) 환자, 1,300명 이상의 알츠하이머병(AD) 환자, 그리고 연령, 성별, 지역이 일치하는 2,400명 이상의 건강한 대조군을 대상으로 간질 유병률과 항경련제 복용량을 비교했습니다. FTD 환자의 평균 진단 연령은 65세(여성 49%)였고, AD 환자의 평균 진단 연령은 72세(여성 59%)였습니다. 전두측두형 치매의 일반적인 발병 연령대는 40세에서 60세 사이이지만, 60세 이후에도 발생할 수 있습니다. 진단 후 평균 수명은 약 8-10년입니다. 의료 분야에 미치는 영향이 크기 때문에 전두측두형 치매는 예측 기간 동안 상당한 증가를 보일 것으로 예상됩니다.

주요 시장 성장 촉진요인

FTD 치료 개발 증가 및 자금 증가

비영리 단체, 질병 옹호 단체, 그리고 민간 단체들은 현재 환자 수가 증가함에 따라 전두측두엽 변성(FTD) 치료제 개발 지원에 집중하고 있습니다.

주요 시장 과제

신경 질환의 오진

다발성 전두측두엽 장애는 우울증, 파킨슨병, 알츠하이머병 또는 기타 정신 질환으로 오진되는 경우가 많습니다. 이는 신경계 질환에 대한 적절한 치료를 시행하는 데 방해가 됩니다. 오진은 기저 전두측두엽 장애(FTD)에 대한 적절한 치료 시작을 지연시키는 경우가 많습니다.

주요 시장 동향

의약품 승인 증가 및 치료 고도화

약물 승인은 환자에게 질병 진행을 늦추고, 증상을 관리하며, 삶의 질을 향상시킬 수 있는 치료법에 대한 접근성을 제공합니다. 이는 전두측두엽성 근위축증(FTD) 환자와 의료 제공자의 치료 수요 증가로 이어집니다. 효과적인 치료법은 종종 향상된 진단 방법, 바이오마커, 그리고 스크리닝 도구를 통해 제공됩니다.

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 임상 검사 분석

제6장 세계의 전두측두엽 치매 시장 전망

제7장 북미의 전두측두엽 치매 시장 전망

제8장 유럽의 전두측두엽 치매 시장 전망

제9장 아시아태평양 전두측두엽 치매 시장 전망

제10장 남미의 전두측두엽 치매 시장 전망

제11장 중동 및 아프리카의 전두측두엽 치매 시장 전망

제12장 시장 역학

제13장 시장 동향과 발전

제14장 세계의 전두측두엽 치매 시장 : SWOT 분석

제15장 Porter's Five Forces 분석

제16장 경쟁 구도

제17장 전략적 제안

제18장 기업 소개와 면책사항

JHS
영문 목차

영문목차

Global Frontotemporal Dementia Market was valued at USD 241.36 Million in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 6.39% through 2030F. Frontotemporal diseases are a neurological condition characterized by the degeneration of nerve cells in the frontal or temporal lobes of the brain. This condition, which includes dementia, progressive supranuclear palsy, and primary progressive aphasia, significantly impacts behavior, language, movement, and personality, thereby impairing individuals' ability to perform daily activities. Frontotemporal disorders, also known as frontotemporal lobar degeneration, are a type of brain disorder that primarily affects the frontal and temporal lobes. This condition is characterized by the progressive loss of nerve cells and the development of dementia.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 241.36 Million
Market Size 2030USD 347.18 Million
CAGR 2025-20306.39%
Fastest Growing SegmentCognitive Enhancers
Largest MarketNorth America

For instance, a 2025 study from Finland compared epilepsy prevalence and antiseizure medication use among 245 frontotemporal dementia (FTD) patients, over 1,300 Alzheimer's disease (AD) patients, and more than 2,400 age-, sex-, and location-matched healthy controls. FTD patients had a mean diagnosis age of 65 (49% women), while AD patients averaged 72 years (59% women). The typical age range for the onset of frontotemporal disorder is between 40 and 60 years, although it can occur after the age of 60. Following diagnosis, the average life expectancy is approximately 8-10 years. Given its significant impact on the healthcare sector, it is projected that frontotemporal disorders will experience substantial growth in the forecast period.

Key Market Drivers

Increasing FTD Drug Development and Increasing Funds

Non-profit organizations and disease advocacy groups, as well as private organizations, are currently focused on supporting the development of drugs for Frontotemporal Degeneration (FTD) due to the expanding patient population. Research funding initiatives from notable non-profit organizations, such as the Association for Frontotemporal Degeneration (AFTD), Bluefield Project Organization, Tau Consortium Organization, Alzheimer Discovery Foundation (ADDF), and CurePSP, Inc., have played a significant role in stimulating research efforts for the treatment of frontotemporal disorders. These organizations provide support for both clinical and preclinical trials aimed at testing novel therapeutics that can intervene to slow down or halt the progression of FTD and other rare neurological diseases. This, in turn, contributes to the growth of the market. For instance, a 2025 study revealed that epileptic seizures are significantly more common in patients with frontotemporal dementia (FTD) than previously believed. This finding enhances understanding of FTD symptoms and highlights the need to consider seizures in patient care. Led by Neurocenter Finland, the University of Eastern Finland and University of Oulu conducted the research, published in JAMA Neurology, using one of the world's largest FTD datasets.

Grants and funding provide resources to support FTD-focused research initiatives. This includes investigations into the underlying mechanisms of the disease, identification of potential drug targets, and the development of novel therapeutic approaches. Drug development in FTD necessitates rigorous clinical trials to evaluate the safety and efficacy of potential treatments. Grants and funding support the design, implementation, and monitoring of these trials, facilitating the testing of new therapies. Adequate funding enhances the attractiveness of FTD research for scientists and researchers. This can lead to increased participation, collaboration, and expertise focused on FTD drug development efforts. Funding enables the exploration of innovative therapeutic strategies, including small molecules, biologics, gene therapies, and personalized medicine approaches tailored to the unique characteristics of FTD patients. Grants and funding assist in the identification and validation of promising drug targets for FTD. This step is crucial in developing treatments that address the underlying causes of the disease.

Key Market Challenges

Misdiagnosis of Neurological Disorders

Multiple frontotemporal disorders are frequently misdiagnosed as depression, Parkinson's disease, Alzheimer's disease, or other psychiatric conditions. This hinders the potential for implementing appropriate treatment for neurological conditions. Misdiagnosis often leads to delayed initiation of appropriate treatment for the underlying FTD. This can result in missed opportunities for interventions that could slow disease progression or manage symptoms effectively. Treating FTD patients based on misdiagnosed conditions can result in ineffective or even harmful treatments. Medications commonly used for depression or other psychiatric disorders may not address the specific cognitive, behavioral, and functional challenges of FTD. Without proper treatment, FTD symptoms can worsen over time, leading to greater impairment in daily functioning and quality of life. Misdiagnosis can lead to unnecessary medical expenses, as well as wasted time and resources on treatments that are unlikely to be effective. Accurate diagnosis is crucial for enrolling eligible patients in clinical trials for FTD-specific treatments. Misdiagnosis can exclude patients from potential participation and hinder the development of targeted therapies.

Key Market Trends

Higher Drug Approvals and Advanced Treatment

Several antidepressant drugs are utilized for the treatment of major depressive disorders and other conditions, such as dysthymia, obsessive-compulsive disorder (OCD), anxiety disorders, eating disorders, chronic pain, and neuropathic pain. For example, in October 2018, Lundbeck introduced Brintellix tablets for the treatment of Major Depressive Disorder in India. Similarly, in April 2019, Lupin launched antidepressant Fluoxetine tablets in the American market, specifically for the treatment of major depressive disorder and obsessive-compulsive disorder. These initiatives contribute significantly to the growth of the market.

Drug approvals provide patients with access to treatments that can potentially slow down disease progression, manage symptoms, and improve quality of life. This leads to higher demand for treatments among FTD patients and healthcare providers. Effective treatments often come with improved diagnostic methods, biomarkers, and screening tools. This facilitates early diagnosis and patient identification, leading to an increased pool of eligible patients seeking treatment. Approved treatments can contribute to better patient outcomes, including improved cognitive function, reduced behavioral symptoms, and enhanced daily functioning. Positive outcomes drive higher demand for these treatments. Drug approvals garner media attention and raise awareness among patients, caregivers, and the general public. This increased awareness leads to more individuals seeking diagnosis and treatment options for FTD. Successful drug approvals indicate a growing interest in FTD research and development. This encourages pharmaceutical companies, researchers, and investors to invest more resources into finding innovative treatments.

Key Market Players

Report Scope:

In this report, the Global Frontotemporal Dementia Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Frontotemporal Dementia Market, By Drug Class:

Frontotemporal Dementia Market, By Disease Indication:

Frontotemporal Dementia Market, By Distribution Channel:

Frontotemporal Dementia Market, By Region:

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Frontotemporal Dementia Market.

Available Customizations:

Global Frontotemporal Dementia market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Clinical Trial Analysis

6. Global Frontotemporal Dementia Market Outlook

7. North America Frontotemporal Dementia Market Outlook

8. Europe Frontotemporal Dementia Market Outlook

9. Asia-Pacific Frontotemporal Dementia Market Outlook

10. South America Frontotemporal Dementia Market Outlook

11. Middle East and Africa Frontotemporal Dementia Market Outlook

12. Market Dynamics

13. Market Trends & Developments

14. Global Frontotemporal Dementia Market: SWOT Analysis

15. Porter's Five Forces Analysis

16. Competitive Landscape

17. Strategic Recommendations

18. About Us & Disclaimer

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기